1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Viatris Inc (VTRS)
  7. Quote


Viatris Stock Price

0.02 (0.16%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 8,352,907
Bid Price 12.20
Ask Price 12.25
News -
Day High 12.29


52 Week Range


Day Low 12.085
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Viatris Inc VTRS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.02 0.16% 12.22 20:00:00
Open Price Low Price High Price Close Price Prev Close
12.23 12.085 12.29 12.195 12.20
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
45,599 8,352,907 $ 12.19 $ 101,818,570 - 11.96 - 18.86
Last Trade Time Type Quantity Stock Price Currency
19:48:43 50 $ 12.23 USD


Draw Mode:

Viatris Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 14.78B 1.21B 1.08B $ 11.95B $ -1.35B -1.11 -5.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 3.61% 11/22/21 12.44k 0.30%

more financials information »

Viatris News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTRS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week12.8512.9011.9612.3714,069,031-0.63-4.9%
1 Month13.7514.8711.9613.3812,231,578-1.53-11.13%
3 Months14.3714.8711.9613.499,043,579-2.15-14.96%
6 Months15.4415.9211.9613.977,788,063-3.22-20.85%
1 Year17.135818.8611.9615.029,461,488-4.92-28.69%
3 Years16.4618.8611.9615.209,990,858-4.24-25.76%
5 Years16.4618.8611.9615.209,990,858-4.24-25.76%

Viatris Description

The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.